Voyager Acquisition Corp

VERAXA Biotech has announced a collaboration with AI specialist Ardigen to support its growing BiTAC pipeline of T cell engagers and antibody drug conjugates. The partnership will initially focus on developing AI-enabled tools and models to guide the selection of synergistic cancer target pairs for VERAXA's proprietary BiTAC programs. VERAXA's BiTAC-TCEs and future BiTAC-ADCs use a Boolean AND-gate logic requiring co-expression of two distinct targets on the same cancer cell for activation, aiming to widen the therapeutic window and reduce toxicity. The collaboration is part of VERAXA's strategy to integrate AI into research and development with the long-term goal of exceeding industry success rates in drug development.

VERAXA Biotech AG announced that BiTAC molecules will become the company's main value drivers and dominate its pipeline development, receiving the largest share of investments with the goal of having a first BiTAC-T cell engager candidate ready by early 2028. The company stated its half-year progress aligns with its pipeline and partnering strategy, and it will finance growth by early monetizing selected non-BiTAC assets. Chief Business Officer Heinz Schwer noted that interest in T cell engager and ADC technologies remains at a record high in the pharmaceutical industry, and the recent BIO International Partnering Conference provided a timely opportunity to meet potential new partners and advance ongoing discussions.

VERAXA Biotech has initiated cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation. The company's Vice President of Research and Development, Christoph Erkel, stated that this step follows encouraging preclinical data presented at AACR and underscores the commitment to accelerate the development of its growing BiTAC-TCE portfolio.

Strategic licensing agreements and acquisitions in antibody-drug conjugates and T-cell engager therapeutics continue to create significant value for platform companies well before pivotal clinical trials. The Jazz Pharmaceuticals–AbCellera collaboration exemplifies how differentiated antibody technologies can command substantial financial commitments prior to clinical development. VERAXA Biotech AG is positioning its technology platform across both ADCs and T-cell engagers, two modalities that continue to attract strategic partnerships. Recent transactions demonstrate that pharmaceutical companies are actively seeking access to differentiated antibody engineering capabilities rather than waiting for late-stage clinical assets.

VERAXA Biotech AG has expanded its research and development facility in Heidelberg, Germany, increasing laboratory space by more than 60% to support team growth and accelerate its cancer therapy programs toward clinical development. The expansion strengthens research capabilities while allowing the company to remain in Heidelberg's leading medical oncology hub and deepen collaborations with top research institutions. Chief Financial Officer Torsten Bürgermeister said securing the necessary space for the growing R&D organization was vital as the company expands internal drug development activities and plans for an increased level of research activities within therapeutic alliances.

Veraxa Biotech AG reported in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for the platform at the BIO International Convention in San Diego, California, taking place June 22-25, 2026. Chief Business Officer Heinz Schwer stated that following the company's recent Nasdaq listing, the convention is an ideal opportunity to detail how the platform can potentially benefit cancer patients.